Bayer shifts US glyphosate business to Ruveon after seeking tariffs on Chinese imports

Bayer is restructuring its U.S. glyphosate business, creating a new entity called Ruveon to house the operations. This significant strategic shift comes as the German pharmaceutical and life sciences giant continues to grapple with extensive litigation over the alleged health risks of glyphosate, the active ingredient in its Roundup weedkiller.

The company has faced thousands of lawsuits in the United States claiming that exposure to glyphosate causes cancer. While Bayer maintains that glyphosate is safe when used as directed and not carcinogenic, the legal battles have resulted in substantial financial liabilities and reputational damage. The creation of Ruveon is seen as a move to isolate the glyphosate business and its associated legal risks from Bayer's core pharmaceutical and agricultural operations.

This restructuring is part of Bayer's ongoing efforts to manage the fallout from its 2018 acquisition of Monsanto, which included the Roundup business. By establishing Ruveon, Bayer aims to ring-fence the legal liabilities and potentially create a more manageable structure for the glyphosate product line, thereby safeguarding the broader company's financial health and strategic focus on innovation in other areas.